Delays Plague Breast and Ovarian Cancer Research

Regulations Slow New Drugs Targeting BRCA Mutations

By Karen Iris Tucker

Published August 14, 2012, issue of August 17, 2012.
  • Print
  • Share Share
  • Single Page

Regulatory hurdles, along with dosing problems, have come to plague a new class of cancer drugs that showed highly encouraging results in early research. Those obstacles have frustrated breast and ovarian cancer patients who are carriers of cancer-causing mutations, particularly prevalent among Ashkenazi Jews, and for whom it was hoped the medicines would prove especially helpful.

Sue Friedman: The founder of FORCE speaks at its annual meeting supporting those with BRCA mutations.
Courtesy Sue Friedman
Sue Friedman: The founder of FORCE speaks at its annual meeting supporting those with BRCA mutations.

Last December, patients eagerly anticipating the completion of trials and FDA approval of Olaparib — then the farthest along in research involving a novel class of therapies called “PARP inhibitors” — were dealt a blow when maker AstraZeneca announced it was, for the time being, discontinuing its late-stage Phase III trial of the drug on patients with serous ovarian cancer, the most common form.

The pharmaceutical company said that Olaparib’s previously reported impressive ability to halt progression of the disease for a time, with limited side effects, would not likely translate into “overall survival benefit,” or the length of time patients live after starting the drug.

No PARP inhibitors are currently in large-scale Phase III trials — the last stage of testing before a company can win FDA approval. But multiple Phase I and II trials are underway. Some early trials indicated that the drugs might prove particularly effective in patients with the inherited BRCA1 or BRCA2 genetic mutations involved in 5% to 10% of all breast and ovarian cancers. With about a one-in-40 chance of carrying a BRCA mutation, Ashkenazi Jews are at higher risk for those diseases compared with those in the general population, where about one in 500 carry a BRCA mutation.

Some academics view the delays in PARP trials as reflective of a contentious change in regulatory policy, regarding how new drugs are evaluated. Dr. Mary Daly, who chairs the department of clinical genetics at Fox Chase Cancer Center in Philadelphia, said: “The move is to thinking that it is not enough to put off progression with a drug, but that the drug has to actually extend life. It’s still somewhat controversial, because some argue that prolonging progression-free survival is valuable in itself.”

Olaparib researchers also reported difficulty in identifying a suitable tablet dose for use in a Phase III trial. AstraZeneca is currently reformulating Olaparib into higher-dose capsules, but the process may significantly delay completion of the clinical trial.

Other PARP inhibitors face similar problems.


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • “'I made a new friend,' my son told his grandfather later that day. 'I don’t know her name, but she was very nice. We met on the bus.' Welcome to Israel."
  • A Jewish female sword swallower. It's as cool as it sounds (and looks)!
  • Why did David Menachem Gordon join the IDF? In his own words: "The Israel Defense Forces is an army that fights for her nation’s survival and the absence of its warriors equals destruction from numerous regional foes. America is not quite under the threat of total annihilation… Simply put, I felt I was needed more in Israel than in the United States."
  • Leonard Fein's most enduring legacy may be his rejection of dualism: the idea that Jews must choose between assertiveness and compassion, between tribalism and universalism. Steven M. Cohen remembers a great Jewish progressive:
  • BREAKING: Missing lone soldier David Menachem Gordon has been found dead in central Israel. The Ohio native was 21 years old.
  • “They think they can slap on an Amish hat and a long black robe, and they’ve created a Hasid." What do you think of Hollywood's portrayal of Hasidic Jews?
  • “I’ve been doing this since I was a teenager. I didn’t think I would have to do it when I was 90.” Hedy Epstein fled Nazi Germany in 1933 on a Kinderstransport.
  • "A few decades ago, it would have been easy to add Jews to that list of disempowered victims. I could throw in Leo Frank, the victim of mob justice; or otherwise privileged Jewish men denied entrance to elite universities. These days, however, we have to search a lot harder." Are you worried about what's going in on #Ferguson?
  • Will you accept the challenge?
  • In the six years since Dothan launched its relocation program, 8 families have made the jump — but will they stay? We went there to find out:
  • "Jewish Israelis and West Bank Palestinians are witnessing — and living — two very different wars." Naomi Zeveloff's first on-the-ground dispatch from Israel:
  • This deserves a whistle: Lauren Bacall's stylish wardrobe is getting its own museum exhibit at Fashion Institute of Technology.
  • How do you make people laugh when they're fighting on the front lines or ducking bombs?
  • "Hamas and others have dredged up passages form the Quran that demonize Jews horribly. Some imams rail about international Jewish conspiracies. But they’d have a much smaller audience for their ravings if Israel could find a way to lower the flames in the conflict." Do you agree with J.J. Goldberg?
  • How did Tariq Abu Khdeir go from fun-loving Palestinian-American teen to international icon in just a few short weeks? http://jd.fo/d4kkV
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.